EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Catalent's Enterprise Value is $14,925 Mil.
Catalent's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-1,207 Mil. Therefore, Catalent's EV-to-EBIT for today is -12.37.
The historical rank and industry rank for Catalent's EV-to-EBIT or its related term are showing as below:
CTLT'
s EV-to-EBIT Range Over the Past 10 Years
Min: -88.57 Med: 27.61 Max: 90.67
Current: -12.37
During the past 13 years, the highest EV-to-EBIT of Catalent was 90.67. The lowest was -88.57. And the median was 27.61.
CTLT's EV-to-EBIT is ranked worse than 100% of 670
companies
in the Drug Manufacturers industry
Industry Median: 17.115
vs CTLT: -12.37
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Catalent's Enterprise Value for the quarter that ended in Dec. 2023 was $12,902 Mil.
Catalent's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-1,207 Mil. Catalent's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -9.35%.
Catalent EV-to-EBIT Historical Data
The historical data trend for Catalent's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Catalent's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalent's EV-to-EBIT Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Catalent's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Catalent's EV-to-EBIT falls into.
Catalent's current Enterprise Value is $14,925 Mil.
Catalent's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,207 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catalent (NYSE:CTLT) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Catalent's Enterprise Value for the quarter that ended in Dec. 2023 was $12,902 Mil.
Catalent's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,207 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catalent EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Catalent's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTLT has been successfully added to your 